Curocell

Curocell, a cell therapy company founded in 2016 in South Korea, is at the forefront of the fight against cancer with its innovative CAR-T therapies. The company's mission is encapsulated in its slogan, "Fight against hopelessness." Curocell's focus lies in unleashing the body’s immune system to combat both blood cancers and solid cancers through its broad-spectrum CAR-T technologies. What sets Curocell apart is its programmed T cell product candidates, which incorporate T cell modifying technology designed to effectively overcome immune suppression, thus offering greater efficacy than current CAR-T cell technology.

The company recently secured a significant KRW36.00BVenture Round investment on 04 January 2022. The investors that contributed to this round include DS Asset Management, Ryukyung PSG, JX Partners, Seoul Investment Partners, Quad Asset Management, Widwin Investment, Moonchase Asset Management, Stick Ventures, and SK Plasma.

Curocell operates in the Biopharma and Biotechnology industries and is positioned as a key player in the rapidly evolving field of cancer treatment. With its innovative approach and strong financial backing, Curocell is shaping up to be a formidable force in the fight against cancer, offering hope to patients and the healthcare industry at large.